Evidence map›Paper›PMID 39080641›Full record

ArticleJournal of nanobiotechnology2024

Visualizing cancer resistance via nano-quenching and recovery detector of CD44.

Jialin Zeng, Lihua Yang, Lingke Zeng, Chengyu Feng, Yuepeng Yang, Yingying Ye, Wenxin Zhang, Jian He, Chao Zhang

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Photothermal FeJournal of nanobiotechnology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jialin Zeng *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Lihua Yang *Department of Pediatric Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Lingke ZengDepartment of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Chengyu FengDepartment of Pediatric Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Yuepeng YangThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Yingying YeThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Wenxin ZhangDepartment of Pediatric Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. zwxsakura@gmail.com.
Jian HeDepartment of Nuclear Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China. hjxueren@126.com.
Chao ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. czhangsinap@163.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515110845Horizontal Project of Guangzhou KingMed Diagnostics Co., Ltd 2022hxkt0801National Natural Science Foundation of China 82373393President Foundation of Zhujiang Hospital of Southern Medical University yzjj2023ms18Science and Technology Program of Guangzhou 2023A04J0060
6 · The paper itself

Abstract

Drug resistance to chemotherapy in cancers remains significant clinical challenges. CD44 modulates cellular adhesion, migration and growth, which plays a pivotal role in driving cancer resistance and even recurrence. Despite ongoing efforts, accurate, safe, and real-time dynamic monitoring techniques for CD44 expression remain inadequate in guiding the management of drug-resistant cancer treatment. In this study, we developed a nano-quenching and recovery detector of CD44 (Cy3-AptCD44@BPNSs) for visualizing cancer drug resistance. The fluorescence recovery of the detector is directly related to the CD44 expression level on cancer cells, which can be used to indicate the degree of drug resistance. It's confirmed that downregulating CD44 expression on cancer cells results in a corresponding decrease in the fluorescence intensity of the detector, which enables precise and dynamic monitoring of CD44. In addition, the Cy3-AptCD44@BPNSs also exhibited specificity in detecting CD44. This visualizing strategy may open up a wide range of possibilities for rapid recognition to cancer drug resistance, which is more efficient and flexible.

Indexed as

Drug Resistance, NeoplasmHyaluronan ReceptorsAntineoplastic AgentsCell Line, TumorFluorescenceHumansNeoplasmsAntineoplastic AgentsCD44 protein, humanHyaluronan ReceptorsAptamerBlack phosphorus nanosheets (BPNSs)Cancer resistanceCD44Nano-quenching and recovery detector

Identifiers

PMID39080641
PMCPMC11289946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.